We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
+ 34-608-087-655
nsaglio@yahoo.co.uk
Title Image

Blog

Home  /  Funding   /  Glycomine Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation

Glycomine Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation

Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance Glycomine’s substrate replacement therapy for PMM2-CDG (CDG-1a), the most prevalent form in the spectrum of congenital diseases of glycosylation (CDG), into early stage clinical studies.

Read more